Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.

Trial Profile

Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Anastrozole; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PROMISE
  • Most Recent Events

    • 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR357).
    • 04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
    • 04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top